Villani et al. indicated that SGLT2 inhibitor, namely canagliflozin inhibits mitochondrial complex-I resulting in reduced prostate cancer cell proliferation, which was presented in their in vivo and in vitro study (Villani et al., 2016). This evidence concerns the gene SLC5A2 and prostate carcinoma.